Compare Neurocrine Biosciences Inc (NBIX) vs Cactus Inc. Class A Common Stock (WHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Cactus Inc. Class A Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $136.39 (market cap $13.82B), while Cactus Inc. Class A Common Stock trades at $61.66 (market cap $5.02B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.8× Cactus Inc. Class A Common Stock's market cap, and Cactus Inc. Class A Common Stock pays a 0.96% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 24 Days and Cactus Inc. Class A Common Stock for 0 Days on average.
| NBIX | WHD | |
|---|---|---|
Market Cap | $13.82B | $5.02B |
Volume | 1,506,669 | 804,573 |
Sector | Health | Energy |
52-Week High | $185.50 | $73.73 |
52-Week Low | $123.10 | $35.26 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $13.83B | $4.71B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 19.87 and robust profitability, including a net income margin of 20.91% and three consecutive quarterly earnings beats. Recent news highlights pipeline progress and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive given strong earnings momentum and product growth, but risks include execution challenges and pricing pressures. The current price offers a significant discount to the analyst target, presenting a potential opportunity for investors comfortable with the biopharmaceutical sector's inherent volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Cactus Inc. Class A Common Stock
Cactus Inc. designs, manufactures, and rents wellhead and pressure control equipment for oil and gas drilling, completion, and production, operating under the Cactus Wellhead brand.
Read more on WHD →
